Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 400 - Sichuan Kelun-Biotech Biopharmaceutical

Drug Profile

A 400 - Sichuan Kelun-Biotech Biopharmaceutical

Alternative Names: A-400-Sichuan Kelun-Biotech Pharmaceutical; A400 - Sichuan Kelun-Biotech Biopharmaceutical; EP-0031; KL-590586

Latest Information Update: 07 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Kelun-Biotech Biopharmaceutical
  • Developer Ellipses Pharma; Sichuan Kelun-Biotech Biopharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c ret inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Solid tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer; Solid tumours; Thyroid cancer
  • Preclinical Brain metastases

Most Recent Events

  • 01 May 2024 US FDA successfully completes phase I data review of phase I/II for A 400 in Solid tumors
  • 05 Mar 2024 Ellipses Pharma anticipates to submit a New Drug Application (NDA) for A 400
  • 05 Mar 2024 Efficacy data from a phase I/II trial in Solid tumours were released by Ellipses Pharma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top